Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

Summary

The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.

Timeline

Start

2015-09

Primary completion

2016-06

Completion

2016-07

Outcome

Met primary endpoint

release “In a recently completed Phase 2 clinical trial in 72 patients with moderate dry eye syndrome, RGN-259 was found to show statistically significant improvements” regenerx.com ↗

release “Based on U.S. Phase 2 and Phase 2b/3 clinical trials in moderate and severe dry eye syndrome, RGN-259 was found to show statistically significant improvements” regenerx.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RGN-259	Unknown	—	Topical

Indications